brand awareness getting in the US market. top researcher all over the world sharing the latest studies.
Two new patent applications have been filed, expanding the use of BIT225 and other Biotron anti-HIV-1 compounds.
The Company is focused on achieving a commercial outcome for its promising antiviral programs whilst continuing
to progress its clinical HIV-1 program to prepare for more advanced clinical trials, including Phase 3 studies. To this
end, Biotron has engaged an international contract research organisation to complete chronic toxicology studies of
BIT225 to enable the long-term human dosing required for this next stage of clinical development.
BIT Price at posting:
6.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)